Leonard Frank X - Feb 28, 2023 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role: President, CNS Cancers US
Signature: By: /s/ Steven Robbins, Attorney in Fact for Frank X. Leonard
Stock symbol: NVCR
Transactions as of: Feb 28, 2023
Transactions value $: $2,255,244
Form type: 4
Date filed: 3/2/2023, 04:01 PM
Previous filing: Jan 9, 2023
Next filing: Mar 6, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVCR	Ordinary Shares	Award	$0	+18.6K	+40.34%	$0.00	64.8K	Feb 28, 2023	Direct	F1
transaction	NVCR	Ordinary Shares	Sale	-$129K	-1.68K	-2.6%	$76.36	63.1K	Mar 1, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NVCR	Options to Buy Ordinary Shares	Award	$2.38M	+31K		$76.97	31K	Feb 28, 2023	Ordinary Shares	31K	$76.97	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
F2	Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3	Options to buy 30,971 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.